Short Interest in Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Rises By 195.2%

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 278,140 shares, a growth of 195.2% from the April 30th total of 94,217 shares. Based on an average daily trading volume, of 1,597,098 shares, the short-interest ratio is presently 0.2 days. Approximately 1.3% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research note on Friday, April 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cuprina Holdings (Cayman) presently has an average rating of “Sell”.

Cuprina Holdings (Cayman) Stock Down 27.7%

CUPR stock traded down $0.92 during midday trading on Friday, hitting $2.39. The company’s stock had a trading volume of 292,379 shares, compared to its average volume of 283,651. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.07. Cuprina Holdings has a twelve month low of $1.76 and a twelve month high of $76.00. The business has a fifty day moving average price of $2.53.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) last issued its quarterly earnings results on Monday, April 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter.

Cuprina Holdings (Cayman) Company Profile

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.